Yamazaki Mayuko, Sugiura Hidekazu, Iwatani Yosuke, Kyoda Mizuki, Nokiba Hirohiko, Amemiya Nobuyuki, Nitta Kosaku, Tsuchiya Ken
Department of Nephrology, Division of Medicine, Saiseikai Kurihashi Hospital, Saitama, Japan.
Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Case Rep Nephrol. 2019 Mar 5;2019:3580941. doi: 10.1155/2019/3580941. eCollection 2019.
A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.
一名41岁女性在32岁时出现肾病综合征,肾活检诊断为微小病变型肾病综合征。尽管使用泼尼松龙(PSL)和环孢素后病情缓解,但肾病综合征复发。她也开始使用利妥昔单抗(RTX)治疗。RTX治疗后她出现迟发性中性粒细胞减少症(R-LON),17天后病情好转。虽然大多数R-LON病例可自发缓解,但也有死亡病例的报道。本报告旨在对R-LON发出警示,因为未来RTX用于成人肾病综合征的情况预计会增加。